Annual Conference
Speakers
Session 1
Marie Dutarte
Executive Director | EUPATI
Maria Dutarte is the Executive Director of the European Patients’ Academy (EUPATI) since 2020. Maria has previously worked for the European AIDS Treatment Group (EATG) coordinating patient involvement in a number of training initiatives and scientific projects. She has also worked for different scientific and international organisations, e.g. French National Research Center for Scientific Research (CNRS), International AIDS Society (IAS), The Global Fund to Fight AIDS, Tuberculosis and Malaria and The International Foundation for Science (IFS). Her educational background is in International Education and Communications.
Rahel von Rohr
Senior Consultant | anteris helvetia
Rahel von Rohr is a PMP certified project manager with a biomedical engineering degree from ETH Zurich and a strong track record in the medical device and combined product market. In her current position as Senior Consultant at anteris helvetia AG she supports companies in developing and marketing drug device combination products and leads projects from ideation to design transfer, both with small start-ups and global big pharma.
Session 2
Paolo Decuzzi
Senior Scientist and Professor of Biomedical Engineering | Italian Institute of Technology
Dr. Paolo Decuzzi is a Senior Scientist and Professor of Biomedical Engineering at the Italian Institute of Technology (IIT) in Genoa – Italy where, in July 2015, he founded the Laboratory of Nanotechnology for Precision Medicine returning in Europe after 10 years of activities conducted in different Clinical Research Institutions in Houston, Texas – USA. Decuzzi is a board member of multiple scientific associations, institutions, and advisory panels, including the Controlled Release Society, IIT, ERC, and the biotech accelerator program SPARK at Stanford. His multidisciplinary research focuses on the rational design of nanoconstructs and implantable devices for the treatment and imaging of various diseases and the development of AI-based models for optimizing the therapeutic efficacy of drug delivery systems. In this context, Decuzzi has published 200+ scientific contributions and generated 10+ patents. His activities have been funded by multiple organizations, in the US and EU, and private companies totaling over $15 million.
San Pun
TBC | TBC
San Pun, Ph.D. has broad experiences in life sciences, including in different areas of pharmaceutical, clinical and diagnostic industries. He is both an author with top notch publications and an inventor. Recently, he is founding a high-tech startup aiming to provide a personalized medical system in the treatment of thrombosis.
Session 3
Frederik Flöther
Quantum Industry Consultant & Computational Scientist – Life Sciences & Healthcare | IBM
Iain Simpson
Director, Front-End Innovation | Phillips Medisize
Iain is a Commercial Director at Phillips-Medisize, where he is part of a global team developing industry leading solutions and platforms for drug delivery, digital medicine and connected health. He has more than 30-years’ experience in multi-disciplinary technology and product development; the last 20 years have in healthcare and increasingly focused on the use of devices and digital technologies to create product differentiation, improve patient engagement and better measure clinical outcomes in real world settings. He has a degree and PhD in physics both from University College London and an MBE in Technology Management from the Open University. He has published and presented at conferences on drug delivery, digital biomarkers, healthcare technology and technology licensing. He is an associate lecturer at the University of Cambridge in Bioscience Enterprise.
Lada Leyens
Global Regulatory Lead, Clinical Trial Innovation | Roche
Lada Leyens has a background in human genetics, health economics and personalised medicine. She has worked at Health Authorities for over 8 years, mainly as a clinical trial assessor and GCP inspector at Swissmedic. At EMA she was in the specialised disciplines office working in the centralised procedure on clinical pharmacology and pharmacogenomics aspects. Lada joined Roche in 2019, where she works as Global Regulatory Lead on Clinical Trial Innovation and digital health programs. In this role she is working to increase the adoption of innovative methods in Roche’s drug development programs and to increase their acceptance externally. Lada represents Roche in the Clinical Research Expert Group at EFPIA, including its Innovative Clinical Trial pillar.
